pemetrexed + docetaxel
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Oct 1, 2006 → Jun 1, 2010
NCT ID
NCT00391274About pemetrexed + docetaxel
pemetrexed + docetaxel is a phase 3 stage product being developed by Eli Lilly for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00391274. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00391274 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer